Citi Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
October 10, 2024 5:36 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $370.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)
The analyst comments "We attended ALNY's TTR day, where management discussed the launch strategy for Amvuttra in ATTR-cardiomyopathy (CM; supplemental NDA submitted, and we anticipate approval in 2Q25), notably: (1) key patient segments, where ALNY plans to first establish Amvuttra as the 1L... More
BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
October 10, 2024 5:30 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $307.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
The analyst comments "ALNY highlighted the commercial strategy for the Amvuttra launch in ATTR-CM at their TTR Day. Mgmt emphasized the launch strategy will... More
Alnylam Pharma (ALNY) Submits sNDA to FDA for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
October 9, 2024 7:03 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with... More
